In 2024, medmix completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
However, medmix has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
In 2024, the total operational greenhouse gas (GHG) emissions of medmix amounted to 10,231 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2023, the total operational greenhouse gas (GHG) emissions of medmix increased by 82.86%, suggesting that the company faced challenges in reducing its emissions from its core operations.
In 2024, the total Scope 1 emissions of medmix were 4,351 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Since 2022, medmix's Scope 1 emissions have decreased by 19.55%, reflecting a declining long-term trend in Scope 1 emissions over time.
Compared to the previous year (2023), medmix's Scope 1 emissions remained relatively stable, indicating that medmix's emissions have plateaued with no significant change in its operational footprint.
In 2024, medmix reported Scope 2 greenhouse gas (GHG) emissions of 5,880 tCOâ‚‚e using the market-based method.
Since 2022, medmix's Scope 2 greenhouse gas (GHG) emissions (Market-Based) have increased by 280.58%, reflecting a rising long-term trend in Scope 2 emissions over time.
Compared to the previous year (2023), medmix's Scope 2 emissions (Market-Based) rose by 384.35% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy
In 2024, medmix reported its Scope 2 emissions using the market-based method.
In 2024, medmix reported 58,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2024 disclosure of medmix includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.
In 2024, medmix reported total Scope 3 emissions of 58,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Since 2022, medmix's Scope 3 emissions have remained relatively stable, indicating that medmix 's emissions have plateaued with no significant change in its value chain footprint.
Compared to the previous year (2023), medmix's Scope 3 emissions remained relatively stable, indicating that medmix 's emissions have plateaued with no significant change in its value chain footprint.
In 2024, medmix reported a total carbon footprint of 68,231 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 10.7% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.
The largest contributor to medmix's total carbon footprint was Scope 3 emissions, accounting for 85.01% of the company's total carbon footprint, followed by Scope 2 emissions at 8.62%.